{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:18:41Z","timestamp":1784791121514,"version":"3.55.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00108-026-02146-w","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T13:48:38Z","timestamp":1782136118000},"page":"854-861","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Update der Pharmakotherapie bei chronischer Herzinsuffizienz mit reduzierter Ejektionsfraktion: von vier zu sechs S\u00e4ulen?","Update on the pharmacotherapy of chronic heart failure with reduced ejection fraction: from four to six pillars?"],"prefix":"10.1007","volume":"67","author":[{"given":"Gunnar","family":"Klein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"issue":"6","key":"2146_CR1","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/s41591-025-03628-4","volume":"31","author":"JJ Herrmann","year":"2025","unstructured":"Herrmann\u00a0JJ et\u00a0al (2025) Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial. Nat Med 31(6):2062\u20132068","journal-title":"Nat Med"},{"issue":"16","key":"2146_CR2","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1161\/CIRCULATIONAHA.124.073521","volume":"151","author":"S Glargaard","year":"2025","unstructured":"Glargaard\u00a0S et\u00a0al (2025) A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure. Circulation 151(16):1150\u20131161","journal-title":"Circulation"},{"key":"2146_CR3","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa2304968","volume":"389","author":"RJ Mentz","year":"2023","unstructured":"Mentz\u00a0RJ et\u00a0al (2023) Ferric Carboxymaltose in Heart Failure with Iron Deficiency. N Engl J Med 389:975\u2013986","journal-title":"N Engl J Med"},{"issue":"4","key":"2146_CR4","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/ejhf.2810","volume":"25","author":"FJ Graham","year":"2023","unstructured":"Graham\u00a0FJ et\u00a0al (2023) Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis. Eur J Heart Fail 25(4):528\u2013537","journal-title":"Eur J Heart Fail"},{"issue":"10369","key":"2146_CR5","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","volume":"400","author":"PR Kalra","year":"2022","unstructured":"Kalra\u00a0PR et\u00a0al (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 400(10369):2199\u20132209","journal-title":"Lancet"},{"issue":"10266","key":"2146_CR6","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski\u00a0P et\u00a0al (2020) Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 396(10266):1895\u20131904","journal-title":"Lancet"},{"issue":"22","key":"2146_CR7","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1001\/jama.2025.3833","volume":"333","author":"SD Anker","year":"2025","unstructured":"Anker\u00a0SD et\u00a0al (2025) Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical Trial. JAMA 333(22):1965\u20131976","journal-title":"JAMA"},{"issue":"8","key":"2146_CR8","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1038\/s41591-025-03671-1","volume":"31","author":"SD Anker","year":"2025","unstructured":"Anker\u00a0SD et\u00a0al (2025) Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency. Nat Med 31(8):2640\u20132646","journal-title":"Nat Med"},{"key":"2146_CR9","doi-asserted-by":"crossref","unstructured":"The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med, 1997. 336(8): p.\u00a0525\u201333.","DOI":"10.1056\/NEJM199702203360801"},{"key":"2146_CR10","unstructured":"Bavendiek, U., et\u00a0al., Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med, 2025."},{"issue":"20","key":"2146_CR11","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong\u00a0PW et\u00a0al (2020) Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 382(20):1883\u20131893","journal-title":"N Engl J Med"},{"key":"2146_CR12","unstructured":"Butler, J., et\u00a0al., Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a\u00a0double-blind, placebo-controlled, randomised, phase\u00a03\u00a0trial. Lancet, 2025."},{"key":"2146_CR13","unstructured":"Butler, J., et\u00a0al., Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial. Eur Heart J, 2025."},{"key":"2146_CR14","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray\u00a0JJ et\u00a0al (2014) Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med 371:993\u20131004","journal-title":"N Engl J Med"},{"key":"2146_CR15","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray\u00a0JJV et\u00a0al (2019) Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 381:1995","journal-title":"N Engl J Med"},{"key":"2146_CR16","unstructured":"Zannad, F., et\u00a0al., Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. Lancet, 2025."},{"key":"2146_CR17","unstructured":"McDonagh et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021 Sep 21;42(36):3599-3726"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02146-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-026-02146-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02146-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:53:23Z","timestamp":1784789603000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-026-02146-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2146"],"URL":"https:\/\/doi.org\/10.1007\/s00108-026-02146-w","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.\u00a0Klein gibt an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}